News from k-v pharmaceutical company A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 16, 2015, 23:11 ET
Researchers at Takeda and CiRA at Kyoto University, Japan, will collaborate on developing game-changing therapeutics by applying iPS cell and related technologies to pharmaceutical R&D activities, such as drug discovery, cell therapy and drug safety. CiRA Director Shinya Yamanaka, a Nobel laureate for his work on iPS cells, will direct the program, while Takeda provides long-term funding, recommendations on research management, and facilities at Shonan Research Center.

CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research

 Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today that...

Apr 14, 2015, 19:00 ET

FDA Advisory Committee Reviews Takeda's Alogliptin EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceuticals U.S.A. Inc. and Takeda Pharmaceutical Company Limited, ("Takeda") today announced that members of the Endocrinologic and...

Apr 13, 2015, 08:40 ET

Takeda Announces Appointment of New President of U.S. Business Unit

 Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA")...

Apr 01, 2015, 08:03 ET

Rx&D responds to PMPRB report: overall impact of medicines must always be considered

OTTAWA, April 1, 2014 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) acknowledges the Patented Medicines Prices Review Board's...

Mar 30, 2015, 08:00 ET

Par Specialty Pharmaceuticals Launches Nascobal® (Cyanocobalamin, USP) Nasal Spray Single-Use Device Along with Nascobal® Nutrition Direct™ Program

 Par Specialty Pharmaceuticals (formerly Strativa Pharmaceuticals) today announced the launch of Nascobal® Nasal Spray in a single-use...

Mar 27, 2015, 14:08 ET

Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned

MONTREAL, March 27, 2015 /CNW Telbec/ - Russell Williams, President of Canada's Research-Based Pharmaceutical Companies (Rx&D), welcomes the...

Mar 19, 2015, 08:00 ET
Eli Lilly and Company logo.

Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy

 Eli Lilly and Company (NYSE: LLY) and Hanmi Pharmaceutical Co., Ltd. (Hanmi) today announced they have entered into an exclusive license and...

Mar 09, 2015, 20:20 ET

Takeda Announces Publication in The Lancet of a Post Hoc Analysis of Data from the EXAMINE Cardiovascular Safety Outcomes Trial

Takeda Pharmaceutical Company Limited (Takeda) announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular...

Mar 09, 2015, 13:15 ET

Takeda Hosts Investor Briefing on its Global Leadership in Gastroenterology

 Takeda Pharmaceutical Company Limited ("Takeda") today held a briefing for investors and analysts in New York, discussing the company's...

Mar 06, 2015, 09:00 ET

Par Pharmaceutical Announces Fourth-Quarter and Full-Year 2014 Conference Call

 Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Friday, March 13, 2015 at 2:00 p.m. EDT to review...

Feb 10, 2015, 14:12 ET

Rx&D Statement on Mandatory Drug Shortage Reporting

VANCOUVER, Feb. 10, 2015 /CNW/ - Following the Minister of Health's announcement, Russell Williams, President, Canada's Research-Based...

Feb 02, 2015, 08:30 ET
Glyxambi® (empagliflozin/linagliptin) tablet packaging 10/5 mg (left). Glyxambi® (empagliflozin/linagliptin) tablet packaging 25/5 mg (right)

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer...

Jan 12, 2015, 08:00 ET

Prasco and Takeda Enter into Agreement to Market Authorized Generic of Colcrys® (colchicine, USP) in the United States

CINCINNATI and DEERFIELD, Ill., Jan. 12, 2015 /PRNewswire/ -- Prasco Laboratories ("Prasco"), Takeda Pharmaceutical Company Limited...

Nov 12, 2014, 07:30 ET

Par Pharmaceutical Announces First FDA Approval of Vasostrict™ (vasopressin injection, USP)

 Par Pharmaceutical Companies, Inc. today announced that it has received approval for its New Drug Application (NDA) for Vasostrict™...

Nov 06, 2014, 08:30 ET

Par Pharmaceutical Announces Quarterly Conference Call

 Par Pharmaceutical Companies, Inc. announced today that it will host a conference call on Thursday, November 13, 2014 at 9:00 a.m. EST to...

Oct 27, 2014, 11:00 ET

Trate los síntomas del reflujo gracias a la Food4GERD App

La enfermedad del reflujo gastroesofágico (GERD), a menudo conocida como ardor de estómago, es un problema importante para muchas...

Oct 20, 2014, 08:00 ET

Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults

 Takeda Pharmaceutical Company Limited ("Takeda"), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen®...

Sep 30, 2014, 07:30 ET

Par Pharmaceutical Begins Shipment of Generic Exforge®

 Par Pharmaceutical Companies, Inc. today announced that it has begun shipping all four strengths of amlodipine and valsartan tablets, the...

Sep 08, 2014, 12:24 ET

Par Pharmaceutical Resumes Shipment of Generic Precedex® Injection

Par Pharmaceutical Companies, Inc. today announced that it has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL,...

Aug 28, 2014, 12:09 ET

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from...